written by reader Scheduled for June 23 rd the CD19 Vaccine for cancer.

By backoffice, June 15, 2017

A small company located in Texas will release it’s findings and results
from 110 clinical trials on a treatment centered on a patients immune
system where the T cell will recognize and phagotize the cancer cell.
The release of their findings should lead to licensing fees that should
cause the price of the stock to explode.

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.

guest

12345

This site uses Akismet to reduce spam. Learn how your comment data is processed.

190 Comments
Inline Feedbacks
View all comments
judith617
judith617
3 years ago

This is just now:
BLCM Bellicum Pharmaceuticals Inc $0.20 (1.52%) $20.00 $49.05 (3.82%)

MBRX Moleculin Biotech Inc $0.98 (49.49%) $98.00 $100.05 (51.06%)

So far is good!

Add a Topic
4668
👍 1
Alex
Alex
3 years ago
Reply to  judith617

Hello Judith, iebought blcm and mbrx, what do you mean ?

judith617
judith617
3 years ago
Reply to  Alex

Hi! Today unfortunately the BLCM last the earlier gain, the MBRX _2.74%. But this 2 stocks long term holding I think.

Alan
Alan
3 years ago

It’s amazing how there haven’t been any updates from these people trying to sell their expensive memberships about where they think the stock was going to go to and no response on the 1000% the stock was supposed to go to after the so called announcement from Bellicum after the trials.

Add a Topic
5971
Add a Topic
5971
judith617
judith617
3 years ago
Reply to  Alan

Hi! I just cancelled one of their so called membership for $2497,- !!! Yes they are very quiet! But we have here couple of very smart people, luckily they inform us with there blogs, just need to keep up reading.

RITA K
RITA K
3 years ago

Any updates on BLCM stock, now that the 23rd. is past?

Add a Topic
5971
Richard
Richard
3 years ago

Its strange and interesting since June 20 – BLCM traded at $12.65 and now its at $11.98, while Moleculin Biotech traded at $1.01 to $2.99 respectively – 200% increase!! I agree .. BLCM maybe a long hold, but got to be watched closely because its a small company.

ronaroosky
3 years ago

BLCM bounced around a bit today and looks like they closed at $12.03, off about 10% since I bought it. Looks like it’s going to be a long ride. I hope they strike gold soon!

Add a Topic
210
Anthony Lasorsa
Anthony Lasorsa
3 years ago

People bought into that a while back. And then they use you to buy into cap off their profits and then they sell the stock and you’re left with nothing.

Add a Topic
5971
Tom
Tom
3 years ago

I think this is BS. Why announce the. Results in Spain? If the results are so great why did it not make the news?

Steve
Steve
3 years ago

A look at a 6 month chart for BCLM shows an intermediate term peak about March 21 at $15.50. It has been in a downtrend for the 6 months. This is demonstrated by the stock trend and the On Balance Volume indicator. In other words, while the stock has been aggressively promoted to the public, it appears that insiders have been distributing the stock to the new buyers (errrr, suckers). Last close was at $11.68. You can cast a chart at Stockcharts.com.

Add a Topic
5971
Add a Topic
5971
Add a Topic
5971
Steve
Steve
3 years ago
Reply to  Steve

A further chart look-back shows the highest high for the year made November 14, 2016 at $23.11. Downhill from there. Today’s last price at $11.70.

Steve
Steve
3 years ago

See the following article at Yahoo.com Finance:

Here’s Why Bellicum Pharmaceuticals Fell as Much as 13.8% Today

Add a Topic
4668
stevex
stevex
3 years ago
Reply to  Steve

That is how pre-revenue biotechs fund their research and clinical trials. Do you expect a company to just roll over and die when it doesn’t have enough capital . BLCM only has a 27.04 m float so their new offering results in a higher % dilution than if it had a 100 m float. An investors payoff is if the company is successful the stock price will rise and receive a nice pay out. Of course the opposite could happen also. The stock is trading near the lower resistance level of 11.50. This level has also covered the gap up. Now I am waiting to see if it breaks resistance drops or bounces and goes up. Bounces up, I sell. Drops down around 10.50 I buy. There are going to be a lot of ups and downs. At the bottom of the motley fool article there was a bit of good news: The silver lining, if there is one, is that Bellicum Pharmaceuticals does appear to be making headway within its pipeline.

Add a Topic
5971
Add a Topic
372
Add a Topic
5971
Steve
Steve
3 years ago
Reply to  stevex

The reality of how start-ups fund their research before earnings is essential to know. It often differs from the great expectations created by promoters who may lead prospective investors to anticipate a trip to the moon at the next company announcement.

Sal
Sal
3 years ago

AVEO is something to watch!!

Pete
Pete
3 years ago
Reply to  Sal

Thanks Sal for the head’s up…Pete from Rochester Hills, MI…it’s hard to know which way is up in biotech as I am new to this market segment.

Tammy
Tammy
3 years ago
Reply to  Sal

What does Afro stand for?